Catapult Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Catapult Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-75,000	Closed	-$5.18M	–	250
2015 Q2	$5.18M	Buy	75,000 +30,000	+67%	+$1.89M	0.74%	32
2015 Q1	$2.46M	Sell	45,000 -65,000	-59%	-$3.1M	0.3%	115
2014 Q4	$4.69M	Buy	110,000 +5,000	+5%	+$181K	1.19%	23
2014 Q3	$3.35M	Buy	105,000 +70,000	+200%	+$1.49M	0.36%	92
2014 Q2	$725K	Buy	+35,000	New	+$647K	0.08%	168

Other funds holding AMAG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catapult Capital Management's AMAG Position: Q3 2015 in Review

Catapult Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q3 2015, closing a stake of 75,000 shares — an estimated $5.18M sold.

Catapult Capital Management first reported a position in AMAG in Q2 2014 and held it in 5 quarters. The position peaked at $5.18M in Q2 2015. 210 funds tracked by Wall St. Rank hold AMAG as of Q3 2015.

Catapult Capital Management reported no remaining AMAG Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Catapult Capital Management sold 75,000 AMAG Pharmaceuticals shares in Q3 2015, an estimated $5.18M.
Catapult Capital Management first reported a position in AMAG Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Catapult Capital Management's AMAG Pharmaceuticals position peaked at $5.18M in Q2 2015.
210 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.